.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,087,241

« Back to Dashboard

Details for Patent: 7,087,241

Title:Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
Inventor(s): Sanders; Steven W. (Salt Lake City, UT), Ebert; Charles D. (Salt Lake City, UT)
Assignee: Watson Laboratories, Inc. (Salt Lake City, UT)
Filing Date:Oct 07, 2005
Application Number:11/246,558
Claims:1. A method of treating with oxybutynin a subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of: a administering a transmucosal formulation, comprising oxybutynin to a subject to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5:1 to about 5:1, wherein the transmucosal formulation optionally includes a permeation enhancer, and wherein the transmucosal formulation is selected from the group consisting of a buccal tablet, a sublingual tablet, or an adhesive film.

2. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 1:1 to about 5:1.

3. The method of claim 1, wherein the AUC ratio of oxybutynin to an oxybutynin metabolite is from about 0.8:1 to about 1.5:1.

4. The method of claim 1, wherein the oxybutynin in the plasma is (R)-oxybutynin, (S)-oxybutynin, or a combination thereof.

5. The method of claim 4, wherein the metabolite of oxybutynin is N-desethyloxybutynin.

6. The method of claim 5, wherein the N-desethyloxybutynin is (R)-N-desethyloxybutynin, (S)-N-desethyloxybutynin or a combination thereof.

7. The method of claim 4, wherein the AUC ratio of (R)-oxybutynin to (S)-oxybutynin is about 0.7:1.

8. The method of claim 6, wherein the AUC ratio of (R)-N-desethyloxybutynin to (R)-oxybutynin is from about 0.4:1 to about 1.6:1.

9. The method of claim 8, wherein the AUC ratio of (R)-N-desethyloxybutynin to (R)-oxybutynin is about 1:1.

10. The method of claim 6, wherein the AUC ratio of (R)-N-desethyloxybutynin to (S)-N-desethyloxybutynin is from about 0.5:1 to about 1.3:1.

11. The method of claim 10, wherein the AUC ratio of (R)-N-desethyloxybutynin to (S)-N-desethyloxybutynin is about 0.9:1.

12. The method of claim 1, wherein a metabolite plasma concentration reaches a peak plasma value of less than about 8 ng/ml.

13. The method of claim 1, wherein a metabolite plasma concentration reaches a peak value of less than about 5 ng/ml.

14. The method of claim 1, wherein the adverse drug experience is an experience selected from the group consisting of: gastrointestinal/genitourinary, nervous system, cardiovascular, dermatological, and opthalmic experiences, or a combination thereof.

15. The method of claim 1, where the permeation enhancer is a member selected from the group consisting essentially of: fatty acids, fatty acid esters, fatty alcohols, fatty acid esters of lactic acid or glycolic acid, glycerol triesters, glycerol diesters, glycerol monoesters, triacetin, short chain alcohols, and mixtures thereof.

16. The method of claim 15, wherein the permeation enhancer is triacetin.

17. The method of claim 1, wherein the oxybutynin is a mixture of R-oxybutynin and S-oxybutynin.

18. The method of claim 1, wherein the oxybutynin is R-oxybutynin.

19. The method of claim 1, wherein the oxybutynin is S-oxybutynin.

20. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and a reaches a peak plasma concentration of N-desethyloxybutynin about 0.5 ng/ml to about 8 ng/ml.

21. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and a reaches a peak plasma concentration of N-desethyloxybutynin less than about 5 ng/ml.

22. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and a reaches a peak plasma concentration of N-desethyloxybutynin from about 1.0 ng/ml to about 3 ng/ml.

23. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and the N-desethyloxybutynin AUC does not exceed the oxybutynin AUC by more than a ratio of about 2:1.

24. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and a has a peak plasma concentration of N-desethyloxybutynin 3 ng/ml.

25. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.5:1 to about 4:1.

26. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 1:1 to 5:1.

27. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and the AUC ratio of oxybutynin to N-desethyloxybutynin is from about 0.8:1 to about 2.5:1.

28. The method of claim 3, wherein the metabolite is N-desethyloxybutynin.

29. The method of claim 1, wherein oxybutynin has plasma concentrations about 2.0 ng/ml at about 6 hours after administration.

30. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and the N-desethyloxybutynin has plasma concentrations about 2.0 ng/ml at about 6 hours after administration.

31. The method of claim 1, wherein the metabolite is N-desethyloxybutynin, and oxybutynin and N-desethyloxybutynin have plasma concentrations about 8 ng/ml at about 24 hours after initial administration.

32. The method of claim 1, wherein the metabolite is N-desethyloxybutynin and at steady state, the oxybutynin and N-desethyloxybutynin have plasma concentrations below about 8 ng/ml for the duration of administration.

33. The method of claim 32, wherein the duration of administration is from about 24 to about 96 hours.

34. The method of claim 1, wherein the transmucosal formulation is administered for a duration of from about 24 to about 96 hours.

35. The method of claim 10, wherein a peak plasma concentration and AUC for (R)-N-desethyloxybutynin are about equal to or less than peak plasma concentration and AUC for (S)-N-desethyloxybutynin.

36. The method of claim 8, wherein a peak plasma concentration and AUC for (R)-oxybutynin are approximately equal to peak plasma concentration and AUC for (R)-N-desethyloxybutynin.

37. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration of less than about 4 ng/mL.

38. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration between about 0.25 ng/ml to about 4 ng/ml.

39. The method of claim 6, wherein (R)-N-desethyloxybutynin has a peak plasma concentration of about 1.5 ng/ml.

40. The method of claim 6, wherein (R)-N-desethyloxybutynin has an AUC of about 100 ng.times.hr/ml.

41. The method of claim 6, wherein (R)-N-desethyloxybutynin has an AUC of from about 30 ng.times.hr/ml to about 170 ng.times.hr/ml.

42. The method of claim 6, wherein (R)-N-desethyloxybutynin plasma concentration is below about 1 ng/ml at about 6 hours after initiation of administration.

43. The method of claim 6, wherein (R)-N-desethyloxybutynin plasma concentration is below about 2 ng/ml at about 24 hours after initiation of administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc